Apeloa subsidiary secures key drug registration certificates for Cefdinir Dry Suspension

Zhejiang Apeloa Juta Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Apeloa Pharmaceutical, has obtained drug registration certificates from the National Medical Products Administration for Cefdinir Dry Suspension (1.5g and 3.0g). These approvals classify the product as a Class 3 chemical drug.

Cefdinir Dry Suspension is a third-generation oral cephalosporin antibiotic used for mild to moderate infections in children caused by specific susceptible microorganisms, including acute bacterial otitis media, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections.

This achievement marks the first domestic approval for this product as a generic drug with consistent quality and efficacy, enabling its participation in national medical insurance negotiations and expanding market sales. The cumulative research and development investment for Cefdinir Dry Suspension amounted to RMB 10.2427 million. The domestic market for Cefdinir oral formulations was valued at RMB 760 million in 2024.